Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial StatsDark mode
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT04883970
CLDN18.2 Targeting PET Imaging in Patients With Gastrointestinal Tumors
Overview
The objective of the study is to constrcut a noninvasive approach 124I-18B10(10L) PET/CT to detect the CLDN18.2 expression of tumor lesions in patients with gastrointestinal tumors and to identify patients benefiting from CLDN18.2 targeting treatment.
Sponsor
Peking University Cancer Hospital & Institute
Phase
N/A
Contacts
Hua Zhu (PRINCIPAL_INVESTIGATOR)
ClinicalTrials.gov
NCT04883970Drug / Compound
18B10(10L)
Isotope(s):
IODINE-124
Radioisotope: I-124
Theranostic Role: Imaging
T1/2 (Half-Life): 4.2 Days
Decay Mode: Electron Capture 74.4% and Positron Emission 25.6%
Energy: 2.138 MeV
Decay Daughters: Tellurium-124
Target(s):
- Claudin 18.2
Ligand Class: Antibodies
Eligibility
Inclusion
- 3\. Has at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST V1.1);
- 2\. Patients with Gastrointestinal tumors;
Exclusion
Exclusion criteria not yet provided.
Share your feedback
Help us improve your experience